Log in

950210 Prestige BioPharma Limited KRX · Singapore

Prestige BioPharma (950210) news

Prestige BioPharma Limited is a public biotech or pharmaceutical company listed on KRX under the ticker 950210, recorded under Singapore. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Prestige BioPharma news

We have not published a story on Prestige BioPharma yet. When there is news, it will appear here.

Questions about Prestige BioPharma

What is the ticker symbol of Prestige BioPharma?

Prestige BioPharma Limited trades under the ticker 950210 on KRX.

Where is Prestige BioPharma listed?

Prestige BioPharma Limited is listed on KRX.

Which country or territory is Prestige BioPharma listed under?

Our directory records Prestige BioPharma Limited under Singapore.

What does Prestige BioPharma do?

Our directory classifies Prestige BioPharma Limited as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Prestige BioPharma?

The ISIN recorded for Prestige BioPharma Limited is KR8702070002.

Does aibio.space cover Prestige BioPharma?

aibio.space lists Prestige BioPharma Limited among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Prestige BioPharma?

Companies in our directory listed in the same country and business area as Prestige BioPharma: Embracing Future Holdings, CytoMed Therapeutics, iX Biopharma, Hyphens Pharma International, Cuprina Holdings (Cayman), Haw Par Corporation.

Investor discussion: Prestige BioPharma

Members talk about Prestige BioPharma (950210). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open KRX:950210 on TradingView.

Listing details

Prestige BioPharma Limited is a public biotech or pharmaceutical company listed on KRX under the ticker 950210, recorded under Singapore. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Prestige BioPharma Limited
Ticker
950210
Listing
KRX
Country or territory
Singapore
Business scope
Biotechnology
ISIN
KR8702070002
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.